Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), announced the signing of a licensing agreement with Amgen to develop next generation ADCs.
Amgen will gain access to Synaffix’s antibody conjugation technology platforms comprising GlycoConnect™, HydraSpace™ and select toxSYN™ linker-payloads for one ADC program with the option to exercise exclusive research and commercial licenses for an additional four programs at a later date.
Under the terms of the agreement, Synaffix will be eligible to receive up to $2 billion in payments spanning signature, program nomination and milestone payments, plus tiered royalties on commercial sales which are consistent with the financials of the recently signed licenses of Synaffix ADC technology platform. Amgen will be responsible for the research, development, manufacturing and commercialization of the ADCs and Synaffix will continue to be responsible for the manufacturing of components that are specifically related to its proprietary technologies.
Peter van de Sande, Chief Executive Officer of Synaffix, said: “Synaffix is pleased to partner with Amgen, a world-leading biotechnology company, to enable novel ADC product development that will aid in the transformation of cancer treatment. Synaffix is extremely proud to contribute its ADC-technology and manufacturing expertise to Amgen’s renowned drug development capabilities. This is our 12th licensing agreement to date, which further builds on our achievements from 2022, where we were also very proud to receive multiple awards including Best ADC Technology Platform, Biotech Company of the Year and Business Development Team of the Year.”